ASX Announcements

Jul 2020
Jul 30th, 2020
DEP® docetaxel and gemcitabine combination trial commences
Jul 30th, 2020
Quarterly Cashflow and Activities Report
Jul 27th, 2020
AZD0466 trial opens MD Anderson Cancer Center as a site
Jul 9th, 2020
New Australian site opening for DEP® trials

Jun 2020
Jun 29th, 2020
DEP® irinotecan boosts immuno-oncology in colon cancer models
Jun 23rd, 2020
Multiple DEP® products showcased at AACR 2020
Jun 18th, 2020
Starpharma to present at OTCQX Virtual Investor Conference
Jun 17th, 2020
DEP® lutetium effective in human prostate cancer model
Jun 16th, 2020
VivaGel® BV launched in central and eastern European countries
Jun 16th, 2020
Notice of initial substantial holder

May 2020
May 26th, 2020
Notice of initial substantial holder
May 14th, 2020
Shareholder Update May 2020
May 7th, 2020
DEP® irinotecan phase 2 commences after positive phase 1 results
May 5th, 2020
Starpharma presents at Macquarie Australia Conference

Apr 2020
Apr 15th, 2020
SPL7013 shows significant activity against SARS-CoV-2 (coronavirus)
Apr 7th, 2020
Quarterly Cashflow and Activity Report

Mar 2020
Mar 20th, 2020
Appendix 2A
Mar 4th, 2020
Okamoto licenses VivaGel® antiviral condom in Asian countries
Mar 2nd, 2020
Starpharma appoints David McIntyre and Appendix 3X

Feb 2020
Feb 24th, 2020
Interim Report and Half-Year Financial Results
Feb 13th, 2020
VivaGel BV launched in Asia
Feb 12th, 2020
David McIntyre appointed as non-executive director
Feb 11th, 2020
Starpharma receives US$3M milestone from AstraZeneca

Jan 2020
Jan 30th, 2020
Shareholder Update January 2020
Jan 29th, 2020
Quarterly Cashflow Report
Jan 24th, 2020
Appendix 3B